A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(Allylamino)-17-demethoxy-geldanamycin [17-AAG]) [tanespimycin] in Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL).

Trial Profile

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(Allylamino)-17-demethoxy-geldanamycin [17-AAG]) [tanespimycin] in Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Tanespimycin (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 14 Feb 2008 The expected completion date for this trial is now 1 May 2007.
    • 19 Nov 2007 Status changed from in progress to discontinued.
    • 31 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top